| 1. |
|
|
| 2. |
- Legendre, C. M., et al.
(författare)
-
Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic-Uremic Syndrome
- 2013
-
Ingår i: New England Journal of Medicine. - 0028-4793 .- 1533-4406. ; 368:23, s. 2169-2181
-
Tidskriftsartikel (refereegranskat)abstract
- Background Atypical hemolytic-uremic syndrome is a genetic, life-threatening, chronic disease of complement-mediated thrombotic microangiopathy. Plasma exchange or infusion may transiently maintain normal levels of hematologic measures but does not treat the underlying systemic disease. Methods We conducted two prospective phase 2 trials in which patients with atypical hemolytic-uremic syndrome who were 12 years of age or older received eculizumab for 26 weeks and during long-term extension phases. Patients with low platelet counts and renal damage (in trial 1) and those with renal damage but no decrease in the platelet count of more than 25% for at least 8 weeks during plasma exchange or infusion (in trial 2) were recruited. The primary end points included a change in the platelet count (in trial 1) and thrombotic microangiopathy event-free status (no decrease in the platelet count of >25%, no plasma exchange or infusion, and no initiation of dialysis) (in trial 2). Results A total of 37 patients (17 in trial 1 and 20 in trial 2) received eculizumab for a median of 64 and 62 weeks, respectively. Eculizumab resulted in increases in the platelet count; in trial 1, the mean increase in the count from baseline to week 26 was 73x10(9) per liter (P<0.001). In trial 2, 80% of the patients had thrombotic microangiopathy event-free status. Eculizumab was associated with significant improvement in all secondary end points, with continuous, time-dependent increases in the estimated glomerular filtration rate (GFR). In trial 1, dialysis was discontinued in 4 of 5 patients. Earlier intervention with eculizumab was associated with significantly greater improvement in the estimated GFR. Eculizumab was also associated with improvement in health-related quality of life. No cumulative toxicity of therapy or serious infection-related adverse events, including meningococcal infections, were observed through the extension period. Conclusions Eculizumab inhibited complement-mediated thrombotic microangiopathy and was associated with significant time-dependent improvement in renal function in patients with atypical hemolytic-uremic syndrome.
|
|
| 3. |
- Schoenrock, A., et al.
(författare)
-
Efficient prediction of human protein-protein interactions at a global scale
- 2014
-
Ingår i: Bmc Bioinformatics. - : Springer Science and Business Media LLC. - 1471-2105. ; 15
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Our knowledge of global protein-protein interaction (PPI) networks in complex organisms such as humans is hindered by technical limitations of current methods. Results: On the basis of short co-occurring polypeptide regions, we developed a tool called MP-PIPE capable of predicting a global human PPI network within 3 months. With a recall of 23% at a precision of 82.1%, we predicted 172,132 putative PPIs. We demonstrate the usefulness of these predictions through a range of experiments. Conclusions: The speed and accuracy associated with MP-PIPE can make this a potential tool to study individual human PPI networks (from genomic sequences alone) for personalized medicine.
|
|
| 4. |
- Aziz, Maryam, et al.
(författare)
-
Mobility impact on the end-to-end delay performance for VoIP over LTE
- 2012
-
Ingår i: Procedia Engineering. - Coimbatore : Elsevier. - 1877-7058. ; , s. 491-498
-
Konferensbidrag (refereegranskat)abstract
- Long Term Evolution (LTE) is the last step towards the 4th generation of cellular networks. This revolution is necessitated by the unceasing increase in demand for high speed connection on LTE networks. This paper focuses on the performance evaluation of End-to-End delay under variable mobility speed for VoIP (Voice over IP) in the LTE network. In the course of E2E performance evaluation, realizing simulation approach three scenarios have been modeled using OPNET 16.0. The first one is the baseline network while among other two, one consists of VoIP traffic solely and the other consists of FTP along with VoIP. E2E delay has been measured for both scenarios in various cases under the varying mobility speed of the node. Simulation results have been studied and presented in terms of comparative performance analysis of the three network scenarios. In light of the result analysis, the performance quality of a VoIP network (with and without the presence of additional network traffic) in LTE has been determined and discussed. The simulation results for baseline VoIP network (non-congested) congested VoIP network and congested VoIP with FTP network show that as the speed of node is gradually increased, E2E delay slightly increases.
|
|
| 5. |
- Prashanth, K.G., et al.
(författare)
-
Structural and Mechanical Characterization of Zr 58.5Ti 8.2Cu 14.2Ni 11.4Al 7.7 Bulk Metallic Glass
- 2012
-
Ingår i: Materials. - : MDPI AG. - 1996-1944. ; 5:1, s. 1-11
-
Tidskriftsartikel (refereegranskat)abstract
- Thermal stability, structure and mechanical properties of the multi-component Zr 58.5Ti 8.2Cu 14.2Ni 11.4Al 7.7 bulk metallic glass have been studied in detail. The glassy material displays good thermal stability against crystallization and a fairly large supercooled liquid region of 52 K. During heating, the alloy transforms into a metastable icosahedral quasicrystalline phase in the first stage of crystallization. At high temperatures, the quasicrystalline phase undergoes a transformation to form tetragonal and cubic NiZr 2-type phases. Room-temperature compression tests of the as-cast sample show good mechanical properties, namely, high compressive strength of about 1,630 MPa and fracture strain of 3.3%. This is combined with a density of 6.32 g/cm 3 and values of Poisson's ratio and Young's modulus of 0.377 and 77 GPa, respectively. The mechanical properties of the glass can be further improved by cold rolling. The compressive strength rises to 1,780 MPa and the fracture strain increases to 8.3% for the material cold-rolled to a diameter reduction of 10%.
|
|
| 6. |
|
|
| 7. |
- Sainis, Salil, et al.
(författare)
-
Weibull analysis of the effect of interrupted aging treatments on the fatigue life of components made of cast Aluminium alloy 354
- 2014
-
Ingår i: Advanced Materials Research. - : Trans Tech Publications. - 1022-6680 .- 1662-8985. - 9783037859254 ; 849, s. 223-227
-
Tidskriftsartikel (refereegranskat)abstract
- Cast aluminum alloy 354 is widely used in the automobile industry due to its attractive set of mechanical properties and excellent castability. The compressor wheel in turbochargers, for example, is used for the production of this alloy. Apart from mechanical properties like fracture toughness and tensile strength, the fatigue life of the component is also a critical issue while considering the performance. This study makes an attempt to improve the fatigue life of a component made out of this alloy by subjecting it to interrupted aging cycles similar to T6I4 and T6I6 (discussed in the published literature) instead of the normally used T61 standard aging treatment. Results show that subjecting the material to these interrupted aging treatments gives lower fatigue life than that obtained after subjecting it to standard T61 conditions.Also, T6I4 treatment yields better fatigue life as compared to T6I6.
|
|
| 8. |
- Sainis, Salil, et al.
(författare)
-
Weibull analysis of the effect of modified aging treatments on fatigue life of cast aluminium alloy 354
- 2013
-
Ingår i: Advanced Materials Research. - : Trans Tech Publications. - 1022-6680 .- 1662-8985. - 9783037858509 ; 800, s. 356-360
-
Tidskriftsartikel (refereegranskat)abstract
- Cast aluminium alloy 354 has extensive applications in the automobile industry. Due to its attractive combination of mechanical properties and excellent castability, it is being used in production of automobile components like the compressor wheel for turbochargers. Performance of this component under fatigue loading conditions is a critical issue. The present study explores the possibility of improving the fatigue life of the component by bringing in process changes - (i) adopting a two-step aging treatment in place of the normally used single step aging treatment (ii) adopting a lower artificial aging temperature (171°C) instead of the temperature normally used for artificial aging(188°C) while performing T61 treatment. In all cases Weibull analysis of fatigue test results was carried out. Weibull analysis of Ultimate Tensile Strength (UTS) values obtained after artificial aging at 171°C and 188°C was also carried out. Among the four variants of two-step aging treatment carried out, the one consisting of 100°C for 5 hours followed by 170°C for 5 hours was found to have the best characteristic fatigue life for the components. The modified T61 treatment where aging was carried out at 171°C instead of the normally used 188°C yielded better characteristic fatigue life as well as better Ultimate Tensile Strength (UTS).
|
|
